Evidence map›Paper›PMID 40108758›Full record

ArticleAutophagy2025

Kit-mediated autophagy suppression driven by a viral oncoprotein emerges as a crucial survival mechanism in Merkel cell carcinoma.

Hao Shi, Yajie Yang, Jiwei Gao, Satendra Kumar, Hong Xie, Ziqing Chen, Jiawen Lyu, Harri Sihto, Virve Koljonen, Silvia Vega-Rubin-de-Celis and 11 more

Abstract read
In one paragraph

Article in Autophagy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. The Biological Role and Clinical Significance of BECLIN-1 in Cancer.International journal of molecular sciences · 2025
    Review
  5. HLF transactivatesScience advances · 2025
    Article
  6. EmergingFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hao ShiDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.ORCID 0000-0003-0839-6516
Yajie YangDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Jiwei GaoDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Satendra KumarDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Hong XieDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Ziqing ChenDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Jiawen LyuDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Harri SihtoDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Virve KoljonenDepartment of Plastic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Silvia Vega-Rubin-de-CelisInstitute for Cell Biology (Cancer Research), University Hospital Essen, Essen, Germany.
Vladana VukojevicLaboratory of Experimental Alcohol and Drug Addiction Research, Department of Clinical Neuroscience, Karolinska Institutet; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Filip FarneboDepartment of Molecular Medicine and Surgery, Karolinska Institutet; Clinic for Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden.
Viveca BjörnhagenDepartment of Molecular Medicine and Surgery, Karolinska Institutet; Clinic for Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden.
Anders HöögDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
C Christofer JuhlinDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Linkiat LeeDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Malin WickströmDepartment of Women's and Children's Health, Karolinska Institutet; BioClinicum J5:20, Karolinska University Hospital, Solna, Sweden.
Jürgen C BeckerTranslational Skin Cancer Research, University Medicine Essen, Essen, Germany.
John Inge JohnsenDepartment of Women's and Children's Health, Karolinska Institutet; BioClinicum J5:20, Karolinska University Hospital, Solna, Sweden.
Catharina LarssonDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.
Weng-Onn LuiDepartment of Oncology-Pathology, Karolinska Institutet; BioClinicum J6:20, Karolinska University Hospital, Solna, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The KIT/c-KIT proto-oncogene is frequently over-expressed in Merkel cell carcinoma (MCC), an aggressive skin cancer commonly caused by Merkel cell polyomavirus (MCPyV). Here, we demonstrated that truncated MCPyV-encoded large T-antigen (LT) suppressed macroautophagy/autophagy by stabilizing and sequestering KIT in the paranuclear compartment via binding VPS39. KIT engaged with phosphorylated BECN1, thereby enhancing its association with BCL2 while diminishing its interaction with the PIK3C3 complex. This process ultimately resulted in the suppression of autophagy. Depletion of KIT triggered both autophagy and apoptosis, and decreased LT expression. Conversely, blocking autophagy in KIT-depleted cells restored LT levels and rescued apoptosis. Additionally, stimulating autophagy efficiently increased cell death and inhibited tumor growth of MCC xenografts in mice. These insights into the interplay between MCPyV LT and autophagy regulation reveal important mechanisms by which viral oncoproteins are essential for MCC cell viability. Thus, autophagy-inducing agents represent a therapeutic strategy in advanced MCPyV-associated MCC.

Indexed as

AutophagyCarcinoma, Merkel CellProto-Oncogene Proteins c-kitSkin NeoplasmsAnimalsAntigens, Viral, TumorApoptosisBeclin-1Cell Line, TumorCell SurvivalHumansMerkel cell polyomavirusMiceProto-Oncogene MasAntigens, Viral, TumorBeclin-1MAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-kitAutophagyBECN1KITlarge T antigenMerkel cell carcinomaMerkel cell polyomavirus

Identifiers

PMID40108758
PMCPMC12283026

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.